By Nancy Lapid May 1 (Reuters) - We also report on a new use for artificial intelligence that could help eliminate some ...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...
The first clinical trial to test the tumour-fighting power of a stem-cell-like class of long-lived immune cells suggests that ...
This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...
T-cell therapy is one of oncology's most powerful ideas: Harvest a cancer patient's own immune cells, genetically engineer ...
Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...
There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...
Sam Neill becomes cancer-free after CAR T-cell therapy, offering hope as breakthrough immunotherapy succeeds where ...
Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...
Researchers have developed a sensitive CAR-T therapy that targets 'faint' proteins in solid tumors, potentially transforming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results